lapatinib / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 236 Diseases   42 Trials   42 Trials   3908 News 


«12...89101112131415161718...4849»
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    Journal, IO biomarker:  Venetoclax in Acute Myeloid Leukemia. (Pubmed Central) -  May 6, 2022   
    The management of unfit and older patients with acute myeloid leukemia should be personalized and be the result of evaluating patient- and disease-specific factors that are essential to their care. Combinations that include venetoclax are an increasingly well-documented option for many of them.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects. (Pubmed Central) -  May 4, 2022   
    Furthermore, HER2 allosteric mutants with enhanced covalent homodimerization were characterized by altered pharmacology that reduces the activity of existing anti-HER2 agents, including the monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib. Overall, the MAP-scoring and functional validation analyses provided new insights into the oncogenic activity and therapeutic targeting of HER2 mutations in cancer.
  • ||||||||||  lapatinib / Generic mfg.
    Journal:  Phosphoproteome of signaling by ErbB2 in ovarian cancer cells. (Pubmed Central) -  Apr 28, 2022   
    MARCKS was phosphorylated on stimulation of SKOV-3 cells with EGF that was inhibited by Lapatinib and CP724714 which was dependent on the kinase activity of ErbB2. These results have identified phosphoproteins that are specific to ErbB2 which have not been previously reported and sets the basis for future experiments.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche
    Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_4482;    
    Real-life outcomes of HER2-positive breast cancer patients with brain metastases were presented in this study. We showed that age at diagnosis, number of brain metastasis, number of chemotherapy received with trastuzumab, and had received three different HER2 targetted therapy was prognostic factors for overall survival.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial. (Available On Demand; 294) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_3220;    
    P3
    Statin use was associated with an inferior outcome in pts with HoR+ disease and/or those treated with L+T. Whether this inferior association in statin users may reflect the underlying predisposition factors that can weaken the efficacy of anti-HER2 treatments and whether this effect was observed only in the L+T arm due to the more potent inhibition of the HER2 signaling pathway remain open questions.
  • ||||||||||  Safety and efficacy of monoclonal antibodies and tyrosine kinase inhibitors in advanced breast carcinoma. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1271;    
    Both monoclonal antibodies and tyrosine kinase inhibitors show clinically significant benefits in advanced HER2 positive breast carcinoma. However, more evidence and randomized clinical trials are needed to further establish their role in this rapidly evolving field.MAR = Margetuximab, TRA = Trastuzumab, ZENO = Zenocutuzumab, PER = Pertuzumab, SOC = Standard of Care, NER = Neratinib, CAP = Capecitabine, LAP = Lapatinib, TUC = Tucatinib, POZ = Poziotinib, PbO = Placebo, F.N = Febrile Neutropenia, D = Diarrhea, PPES = Palmar-Plantar Erythrodysesthesia, A = Anemia, N = Neutropenia.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Tukysa (tucatinib) / Seagen
    Association of intrathecal trastuzumab to standard therapy in patients with leptomeningeal metastasis in HER2 positive breast cancer. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1270;    
    However, more evidence and randomized clinical trials are needed to further establish their role in this rapidly evolving field.MAR = Margetuximab, TRA = Trastuzumab, ZENO = Zenocutuzumab, PER = Pertuzumab, SOC = Standard of Care, NER = Neratinib, CAP = Capecitabine, LAP = Lapatinib, TUC = Tucatinib, POZ = Poziotinib, PbO = Placebo, F.N = Febrile Neutropenia, D = Diarrhea, PPES = Palmar-Plantar Erythrodysesthesia, A = Anemia, N = Neutropenia. Intrathecal administration of trastuzumab along with systemic treatment and radiotherapy, might improve or stabilise the consequences of leptomeningeal involvement by HER2-positive breast cancer with manageable toxicity.
  • ||||||||||  lapatinib / Generic mfg., gemcitabine / Generic mfg.
    Journal:  Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance. (Pubmed Central) -  Apr 26, 2022   
    Our data demonstrates that lapatinib can not only inhibit growth of CCA overexpressing HER2, but can also circumvent ABCB1-mediated chemoresistance after gemcitabine treatment. As such, this provides a preclinical rationale basis for further clinical investigation into the effectiveness of a combination treatment of lapatinib with gemcitabine in HER2-overexpressed CCA.
  • ||||||||||  Gilotrif (afatinib) / Boehringer Ingelheim
    Preclinical, Journal:  3D cell culture alters signal transduction and drug response in head and neck squamous cell carcinoma. (Pubmed Central) -  Apr 26, 2022   
    Cell line UM-SCC-11B revealed a strong resistance to lapatinib under 3D cell culture conditions, while a good response to TKI therapy was observed under 2D cell culture conditions...The results of the present study represent an idea of how signalling mechanisms of cancer cells can be changed using different cell culture methods. Overall, 3D cell culture could be an important component in the analysis of resistance mechanisms in cancer therapy.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Clinical, Journal, Adverse events:  A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development. (Pubmed Central) -  Apr 19, 2022   
    Lapatinib may decrease the apoptotic effects in cardiomyocytes by altering the effects of trastuzumab on BCL-X proteins. This patient-centered systems-based approach provides, based on the trastuzumab-induced ADR cardiotoxicity, an example of how to apply reverse translation to investigate ADRs at the molecular pathway and target level to understand the causality and prevalence during drug development of novel therapeutics.
  • ||||||||||  lapatinib / Generic mfg.
    Journal:  Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance. (Pubmed Central) -  Apr 19, 2022   
    Results from both human breast cancer cells with PTPRO knockdown or overexpression and mouse embryonic fibroblasts (MEFs) which derived from Ptpro and Ptpro mice with then stably transfected plasmid FUGW-Erbb2 consistently demonstrated the essentiality of PTPRO in the lapatinib-mediated anticancer process. Our findings suggest that PTPRO is not only able to serve as an independent prognostic indicator, but upregulating PTPRO can also reverse the lapatinib resistance of ERBB2-positive breast cancer.
  • ||||||||||  5-fluorouracil / Generic mfg., lapatinib / Generic mfg.
    Biomarker, Journal, Checkpoint inhibition, Tumor Mutational Burden, IO biomarker:  TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma. (Pubmed Central) -  Apr 17, 2022   
    Our findings suggest that PTPRO is not only able to serve as an independent prognostic indicator, but upregulating PTPRO can also reverse the lapatinib resistance of ERBB2-positive breast cancer. These findings suggest that TET1 mutations may serve as a potential biomarker for the response to ICIs in COAD patients.
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker:  Comprehensive Analysis Revealed the Potential Implications of m6A Regulators in Lung Adenocarcinoma. (Pubmed Central) -  Apr 15, 2022   
    m6A modification was significantly associated with the TME and clinical outcomes. These findings may help gain more insights into the role of m6A decoration in the molecular mechanism of LUAD, thus facilitating the development of more effective personalized treatment strategies.
  • ||||||||||  lapatinib / Generic mfg.
    Journal:  HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib. (Pubmed Central) -  Apr 5, 2022   
    Immuno-phenotyping holds the promise to complement current predictive models in HER2-positive breast cancer and to assist in new therapeutic development. HER3 PET imaging can be used to visualize dynamic changes in HER3 expression that occur in HER2+ breast cancers with HER2 inhibitor treatment and identify those likely to benefit by the addition of combination HER3 and HER2 inhibition.
  • ||||||||||  lapatinib / Generic mfg.
    Journal, Cancer stem cells:  The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells. (Pubmed Central) -  Mar 25, 2022   
    The self-renewal and tube formation abilities of cells were also abolished while CD24 and Oct3/4 levels were reduced, and the MAPK pathway was overactivated. This study shows a potential involvement of the ErbB2/ErbB3 pathway in CSC generation and could lead to new insight into the mechanism of tumorigenesis and the way of cancer prevention.
  • ||||||||||  lapatinib / Generic mfg.
    Journal:  Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. (Pubmed Central) -  Mar 23, 2022   
    We identified four genes with mutations: three genes with known functions (membrane protein, pyrrolidone-carboxylate peptidase, and sensor histidine kinase LytS, respectively) and one gene with unknown function (hypothetical protein). In conclusion, this study indicates that lapatinib significantly inhibits biofilm formation and the hemolytic activity of S. aureus.